KR20220071521A - Anticancer composition comprising dibenzocyclooctadiene lignan derived from fruits Schisandra chinensis - Google Patents

Abstract

The present invention relates to a new anticancer effect of dibenzocyclooctadiene lignin extracted from fruits of schisandra chinensis. When a dibenzocyclooctadiene lignin compound of the present invention extracted from the schisandra chinensis is treated in cancer cells, the compound provides excellent cytotoxicity. Therefore, the compound of the present invention is used as an anticancer use, and treats a cancer patient through this. The new anticancer effect of the dibenzocyclooctadiene lignin of the present invention provides an unknown new use for the dibenzocyclooctadiene lignin, and is usefully used in improvement or treatment of a stomach cancer, a uterine cancer, and a colorectal cancer with the excellent anticancer effect.

Description

Anticancer composition comprising dibenzocyclooctadiene lignan derived from fruits Schisandra chinensis

The present invention relates to an anticancer composition derived from Schisandra, and more specifically, to an anticancer composition and health functional food in which the anticancer effect was confirmed by treating cancer cells with dibenzocyclooctadiene lignan ingredients derived from the fruit of Schisandra. will be.

Cancer is one of the most serious diseases facing mankind, and enormous research is being conducted for cancer treatment. In cancer treatment, especially in the medical treatment of cancer, various anticancer drugs that inhibit the proliferation of cancer cells have been developed and achieved to some extent, but these drugs inhibit the proliferation of normal cells as well as cancer cells, resulting in nausea, vomiting, hair loss, bone marrow. There are problems that cause various side effects such as inhibition, renal failure, and neurological disorders, and various studies are being conducted to develop new anticancer drugs.

As part of this anticancer drug discovery research, research is underway to discover anticancer drugs using natural herbal medicines that are expected to have lower toxicity to the human body compared to synthesized compounds. Although a patent disclosing the treatment of breast cancer using a composition that Therefore, there is a need to develop an anticancer composition that has confirmed the anticancer effect of a material derived from Schisandra.

The present inventors solved the above problems and conducted research to discover a composition having an anticancer effect, and treated the cancer cell line with dibenzocyclooctadiene lignan extracted from the fruit of Schisandra. As a result of observation, it was confirmed that the compound of the present invention has an anticancer effect by confirming that it shows toxicity to cancer cells.

Accordingly, an object of the present invention is to provide a composition for preventing, improving or treating cancer, comprising a compound represented by the following Chemical Formula 1 or Chemical Formula 2, an isomer thereof, or a salt thereof as an active ingredient.

[Formula 1]

[Formula 2]

In Formula 1 or 2,

Wherein R ₁ is a C _1-3 alkoxy group or a hydroxyl group;

wherein R ₂ is a C _1-3 alkoxy group;

wherein R ₃ is a C _1-3 alkoxy group, a hydroxy group or an angeloyl group;

wherein R ₄ is hydrogen or a hydroxyl group;

wherein R ₅ is hydrogen or a benzoyl group; and

Wherein R ₆ is a C _1-3 alkoxy group, a hydroxy group, or an angeloyl group.

However, the technical problem to be achieved by the present invention is not limited to the above-mentioned problems, and other problems not mentioned will be clearly understood by those skilled in the art from the following description.

In order to achieve the above object, the present invention provides a composition for preventing, improving or treating cancer, comprising a compound represented by the following Chemical Formula 1 or Chemical Formula 2, an isomer thereof, or a salt thereof as an active ingredient.

[Formula 1]

[Formula 2]

In Formula 1 or 2,

Wherein R ₁ is a C _1-3 alkoxy group or a hydroxyl group;

wherein R ₂ is a C _1-3 alkoxy group;

wherein R ₃ is a C _1-3 alkoxy group, a hydroxy group or an angeloyl group;

wherein R ₄ is hydrogen or a hydroxyl group;

wherein R ₅ is hydrogen or a benzoyl group; and

Wherein R ₆ is a C _1-3 alkoxy group, a hydroxy group, or an angeloyl group.

In one embodiment of the present invention, the compound may be derived from the fruit of Schisandra.

In another embodiment of the present invention, the compound may be separated by a column chromatography method.

In another embodiment of the present invention, the compound may be selected from the group consisting of (-)-Gomisin K1, Gomisin J, Gomisin A, and Angeloyl gomisin H.

In another embodiment of the present invention, the cancer is brain tumor, head and neck cancer, breast cancer, lung cancer, esophageal cancer, stomach cancer, duodenal cancer, appendix cancer, colorectal cancer, rectal cancer, liver cancer, pancreatic cancer, gallbladder cancer, bile duct cancer, anal cancer, renal cancer, ureter cancer, bladder cancer, prostate cancer, penile cancer, testicular cancer, uterine cancer, ovarian cancer, vulvar cancer, vaginal cancer or skin cancer.

A pharmaceutical composition comprising a dibenzocyclooctadiene lignan compound extracted from the fruit of Schisandra according to the present invention has excellent cytotoxicity against cancer cells, and exhibits anticancer effects on all of gastric cancer, uterine cancer and colorectal cancer. As it has been confirmed that it can be usefully used for the treatment of cancer patients.

However, the effect of the present invention is not limited to the above effect, and it should be understood to include all effects that can be inferred from the configuration of the invention described in the detailed description or claims of the present invention.

1 is a schematic diagram illustrating a separation method of dibenzocyclooctadiene lignan using column chromatography of the present invention.
Figure 2 shows the structure of 7 kinds of dibenzocyclooctadiene lignan (dibenzocyclooctadiene lignan) contained in Schisandra extract of the present invention.
3 is a view showing the anticancer effect of the present invention dibenzocyclooctadiene lignan (dibenzocyclooctadiene lignan) to the cancer cell line and then confirming the degree of apoptosis of the cancer cell line, Figure 3a is a cervical cancer cell line, Figure 3b is a gastric cancer cell line, Figure 3c is This is the result of confirming the degree of apoptosis in colorectal cancer cell lines.

The present inventors conducted a study to discover a composition having an anticancer effect and confirmed that dibenzocyclooctadiene lignan extracted from the fruit of Schisandra showed an anticancer effect on cancer cell lines, thereby providing the present invention has been completed

Accordingly, the present invention provides a pharmaceutical composition for preventing or treating cancer, comprising a compound represented by the following Chemical Formula 1 or Chemical Formula 2, an isomer thereof, or a pharmaceutically acceptable salt thereof as an active ingredient.

[Formula 1]

[Formula 2]

In Formula 1 or 2,

Wherein R ₁ is a C _1-3 alkoxy group or a hydroxyl group;

wherein R ₂ is a C _1-3 alkoxy group;

wherein R ₃ is a C _1-3 alkoxy group, a hydroxy group or an angeloyl group;

wherein R ₄ is hydrogen or a hydroxyl group;

wherein R ₅ is hydrogen or a benzoyl group; and

Wherein R ₆ is a C _1-3 alkoxy group, a hydroxy group, or an angeloyl group.

According to a conventional method known in the art for extracting an extract from a natural product, the Schisandra extract in the present invention, that is, it can be separated using a conventional solvent under conditions of conventional temperature and pressure. In the present invention, the Schisandra extract includes extracts obtained from all parts of the Schisandra plant, preferably extracts of leaves, stems, fruits or roots, and most preferably extracts of Schisandra fruit.

As an extraction solvent for extracting the Schisandra extract of the present invention, a solvent generally used in the extraction process may be used, and two or more different solvents may be sequentially used for extraction. Preferably, the extraction solvent of the present invention is water, anhydrous or hydrous lower alcohols having 1-4 carbon atoms (methanol, ethanol, propanol, butanol), acetone, ethyl acetate, butyl acetate, dichloromethane (CH ₂ Cl ₂ ), chloroform , a solvent selected from the group consisting of hexane and 1,3-butylene glycol may be used, more preferably methanol, n-hexane, dichloromethane, ethyl acetate, or water, most preferably is methanol.

In the present invention, the separation of dibenzocyclooctadiene lignans from the Schisandra extract can be obtained by a conventional method for isolating and purifying a single compound from the extract. For example, filtration using a silica gel or celite gel column, size-exclusion chromatography using liquid column chromatography, ion exchange chromatography, partition chromatography, affinity (affinity) Separation and purification can be carried out using chromatography or a combination of these chromatography.

In the present invention, the compound obtained by the above method may be selected from the group consisting of (-)-Gomisin K1, Gomisin J, Gomisin A, or Angeloyl gomisin H.

In the present invention, "C _1-3 alkoxy group" means an alkyl group having 1 to 3 carbon atoms bonded to oxygen (O), but is not limited thereto, but is not limited thereto, but a methoxy group, an ethoxy group, a propoxy group, or an iso group. It may be a propoxy period.

In the present invention, the "Angeloyl group" may have a molecular formula of C ₅ H ₇ O ₂ and be represented by the following Chemical Formula 3.

[Formula 3]

As used herein, the term “isomer” refers to a compound having the same molecular formula but not the same connection method or spatial arrangement of constituent atoms in a molecule. Isomers include, for example, structural isomers, and stereoisomers.

As used herein, the term “cancer” refers to an aggressive (aggressive) characteristic in which cells divide and grow ignoring the normal growth limit, an invasive characteristic that penetrates into surrounding tissues, and a metastatic (metastatic) characteristic that spreads to other parts of the body. ) is a generic term for diseases caused by cells with

In the present invention, the cancer is not particularly limited in its type, and brain tumor, head and neck cancer, breast cancer, lung cancer, esophageal cancer, stomach cancer, duodenal cancer, appendix cancer, colorectal cancer, rectal cancer, liver cancer, pancreatic cancer, gallbladder cancer, bile duct cancer, anus cancer It may be cancer, renal cancer, ureter cancer, bladder cancer, prostate cancer, penile cancer, testicular cancer, uterine cancer, ovarian cancer, vulvar cancer, vaginal cancer or skin cancer, preferably stomach cancer or uterine cancer, but is not limited thereto.

As used herein, the term “prevention” refers to any act of inhibiting or delaying the onset of cancer by administering the pharmaceutical composition according to the present invention.

As used herein, the term “treatment” refers to any action in which symptoms of cancer are improved or beneficially changed by administration of the pharmaceutical composition according to the present invention.

In the present invention, the anticancer effect of the dibenzocyclooctadiene lignan according to the present invention was confirmed through specific examples.

In one embodiment of the present invention, the dibenzocyclooctadiene lignan derived from Schisandra fruit of the present invention was treated with a compound in gastric cancer cell lines (AGS), uterine cancer cell lines (Hela) and colon cancer cell lines (HT29), and then cytotoxicity was confirmed. As a result, it was confirmed that it has an excellent anticancer effect on all of gastric cancer, uterine cancer and colorectal cancer (see Example 2).

In the present invention, as the salt, an acid addition salt formed by a pharmaceutically acceptable free acid is useful. Acid addition salts include inorganic acids such as hydrochloric acid, nitric acid, phosphoric acid, sulfuric acid, hydrobromic acid, hydroiodic acid, nitrous acid or phosphorous acid and aliphatic mono and dicarboxylates, phenyl-substituted alkanoates, hydroxy alkanoates and alkanes. It is obtained from non-toxic organic acids such as dioates, aromatic acids, aliphatic and aromatic sulfonic acids. Such pharmaceutically non-toxic salts include sulfate, pyrosulfate, bisulfate, sulfite, bisulfite, nitrate, phosphate, monohydrogen phosphate, dihydrogen phosphate, metaphosphate, pyrophosphate chloride, bromide, ioda. Id, fluoride, acetate, propionate, decanoate, caprylate, acrylate, formate, isobutyrate, caprate, heptanoate, propiolate, oxalate, malonate, succinate, suberate , sebacate, fumarate, maleate, butyne-1,4-dioate, hexane-1,6-dioate, benzoate, chlorobenzoate, methylbenzoate, dinitrobenzoate, hydroxybenzoate, methylbenzoate Toxybenzoate, phthalate, terephthalate, benzenesulfonate, toluenesulfonate, chlorobenzenesulfonate, xylenesulfonate, phenylacetate, phenylpropionate, phenylbutyrate, citrate, lactate, β-hydroxybutyrate, glycol late, malate, tartrate, methanesulfonate, propanesulfonate, naphthalene-1-sulfonate, naphthalene-2-sulfonate or mandelate.

The acid addition salt according to the present invention is prepared by a conventional method, for example, by dissolving the compound represented by Formulas 1 to 3 in an excess aqueous acid solution, and dissolving the salt in a water-miscible organic solvent such as methanol, ethanol, acetone or It can be prepared by precipitation using acetonitrile. It can also be prepared by evaporating the solvent or excess acid from the mixture and drying the mixture, or by suction filtration of the precipitated salt.

In addition, a pharmaceutically acceptable metal salt may be prepared using a base. The alkali metal or alkaline earth metal salt is obtained, for example, by dissolving the compound in an excess alkali metal hydroxide or alkaline earth metal hydroxide solution, filtering the undissolved compound salt, and evaporating and drying the filtrate. In this case, it is pharmaceutically suitable to prepare a sodium, potassium or calcium salt as the metal salt. The corresponding silver salt is obtained by reacting an alkali metal or alkaline earth metal salt with a suitable silver salt (eg silver nitrate).

On the other hand, the pharmaceutical composition of the present invention may further include an appropriate carrier, excipient or diluent commonly used in the preparation of the pharmaceutical composition. The composition comprising a pharmaceutically acceptable carrier may be in various oral or parenteral dosage forms. In the case of formulation, it can be prepared using a diluent or excipient such as a filler, extender, binder, wetting agent, disintegrant, surfactant, etc. commonly used. Solid preparations for oral administration may include tablet pills, powders, granules, capsules, etc., and these solid preparations include one or more compounds and at least one excipient, for example, starch, calcium carbonate, sucrose or lactose. It can be prepared by mixing (lactose), gelatin, etc.

In addition to simple excipients, lubricants such as magnesium stearate, talc and the like may also be used. Liquid formulations for oral administration include suspensions, internal solutions, emulsions, syrups, etc. In addition to water and liquid paraffin, which are commonly used simple diluents, various excipients such as wetting agents, sweeteners, fragrances, and preservatives may be included. have. Formulations for parenteral administration may include sterile aqueous solutions, non-aqueous solutions, suspensions, emulsions, lyophilized formulations, and suppositories. As the non-aqueous solvent and suspension solvent, propylene glycol, polyethylene glycol, vegetable oil such as olive oil, etc. may be used. As the base of the suppository, witepsol, macrogol, tween 61, cacao butter, laurin, glycerogelatin, and the like can be used.

In addition, the pharmaceutical composition of the present invention is a group consisting of tablets, pills, powders, granules, capsules, suspensions, internal solutions, emulsions, syrups, sterile aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations and suppositories It may have any one formulation selected from

The pharmaceutical composition of the present invention is administered in a pharmaceutically effective amount.

As used herein, the term "administration" refers to introducing the pharmaceutical composition of the present invention to a subject by any suitable method, and the administration route can be administered through various routes, either oral or parenteral, as long as it can reach the target tissue. .

The pharmaceutical composition of the present invention may be appropriately administered to a subject according to a conventional method, administration route, and dosage used in the art according to purpose or necessity. Examples of routes of administration include oral, parenteral, subcutaneous, intraperitoneal, intrapulmonary, and intranasal administration, and parenteral injection includes intramuscular, intravenous, intraarterial, intraperitoneal or subcutaneous administration.

In addition, an appropriate dosage and number of administration may be selected according to methods known in the art, and the amount and frequency of administration of the pharmaceutical composition of the present invention actually administered depends on the type of symptom to be treated, administration route, sex, health It can be appropriately determined by various factors such as the condition, diet, age and weight of the individual, and the severity of the disease.

As used herein, the term "pharmaceutically effective amount" means an amount sufficient to inhibit or alleviate cancer at a reasonable benefit/risk ratio applicable to medical use, and the effective dose level may vary depending on the type and severity of the subject, age, sex, The activity of the drug, the sensitivity to the drug, the time of administration, the route of administration and the rate of excretion, the duration of treatment, factors including concurrently used drugs, and other factors well known in the medical field may be determined according to factors.

In addition, as another aspect of the present invention, the present invention provides a method for preventing or treating cancer comprising administering the composition to an individual.

As used herein, the term “individual” refers to all animals, including humans, that are likely to or have developed the cancer. By administering the composition of the present invention to a subject, cancer can be alleviated or treated.

As another aspect of the present invention, the present invention provides a health functional food composition for the prevention or improvement of cancer, comprising a compound represented by the following Chemical Formula 1 or Chemical Formula 2, an isomer thereof, or a pharmaceutically acceptable salt thereof as an active ingredient to provide.

[Formula 1]

[Formula 2]

In Formula 1 or 2,

Wherein R ₁ is a C _1-3 alkoxy group or a hydroxyl group;

wherein R ₂ is a C _1-3 alkoxy group;

wherein R ₃ is a C _1-3 alkoxy group, a hydroxy group or an angeloyl group;

wherein R ₄ is hydrogen or a hydroxyl group;

wherein R ₅ is hydrogen or a benzoyl group; and

Wherein R ₆ is a C _1-3 alkoxy group, a hydroxy group, or an angeloyl group.

As used herein, the term “improvement” refers to any action that at least reduces a parameter related to the condition being treated, for example, the degree of pain symptoms.

In the health functional food composition of the present invention, the active ingredient may be added to food as it is or used together with other food or food ingredients, and may be appropriately used according to a conventional method. The mixing amount of the active ingredient may be appropriately determined depending on the purpose of its use (for prevention or improvement). In general, in the production of food or beverage, the composition of the present invention is added in an amount of 15% by weight or less, preferably 10% by weight or less, based on the raw material. However, in the case of long-term intake for health and hygiene or health control, the amount may be less than or equal to the above range.

The health functional food composition of the present invention is not particularly limited in other ingredients other than containing the active ingredient as an essential ingredient in the indicated ratio, and may contain various flavoring agents or natural carbohydrates as additional ingredients like a conventional beverage. have. Examples of the above-mentioned natural carbohydrates include monosaccharides such as glucose, fructose and the like; disaccharides such as maltose, sucrose and the like; and polysaccharides such as conventional sugars such as dextrin and cyclodextrin, and sugar alcohols such as xylitol, sorbitol, and erythritol. As flavoring agents other than those described above, natural flavoring agents (taumatin, stevia extract (eg, rebaudioside A, glycyrrhizin, etc.) and synthetic flavoring agents (saccharin, aspartame, etc.) can be advantageously used. The proportion of the natural carbohydrate can be appropriately determined by the selection of a person skilled in the art.

In addition to the above, the health functional food composition of the present invention includes various nutrients, vitamins, minerals (electrolytes), flavoring agents such as synthetic and natural flavoring agents, colorants and thickeners (cheese, chocolate, etc.), pectic acid and salts thereof, Alginic acid and its salts, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohols, carbonation agents used in carbonated beverages, and the like may be contained. These components may be used independently or in combination. The proportion of these additives may also be appropriately selected by those skilled in the art.

Hereinafter, preferred examples are presented to help the understanding of the present invention. However, the following examples are only provided for easier understanding of the present invention, and the contents of the present invention are not limited by the following examples.

[Example]

Example 1. Isolation and structural identification of dibenzocyclooctadiene lignan derived from Schisandra

The fruit of Ojima was provided from RDA of Eumseong of Korea in 2019 confirmed by Professor Dae-geun Kim of Woosuk University in Jeonju, and the voucher specimen (KHU-NPCL-201904) is stored in Professor Nam-in Paik's laboratory.

Dried omija fruit (5.4 kg) was soaked in 70% ethanol (EtOH) solution at room temperature for 24 hours, filtered through a filter, and the extract was concentrated to obtain a concentrate of 1.3 kg. The concentrate was suspended in H ₂ O (4.2L) and washed sequentially with EtOAc (4.2LX 3) and n-BuOH (3.4LX 3). The separated extract was concentrated to obtain EtOAc (SCE, 329 g), n-BuOH (SCB, 247 g) and H ₂ O (SCW, 723 g) fractions, of which SCE (329 g) was SiO ₂ (silica gel) column chromatography Graph (column chromatography) was used together with octadecyl-silica gel (ODS) and Sephadex LH-20 to separate, and the process is shown in FIG. 1 . The remaining fractions, SCB and SCW, were also separated using the same column chromatography to obtain 7 purified lignans. (Schisandrin A(1), (-)-Gomisin K1(2), Gomisin J(3), Gomisin A(4), Angeloyl gomisin H(5), Schisandrin(6), Gomisin C(7)) indicated.

Example 2. Confirmation of anticancer activity of lignan compounds extracted from Schisandra fruit

2-1. Confirmation of cytotoxicity of lignan compounds

To confirm the anticancer activity of the seven lignans isolated in Example 1, rat macrophages (Raw264.7) and gastric cancer cells seeded on an amplifier coverslip of a 6-well plate. (AGS), cervical cancer cells (Hela) and colon cancer cells (HT29) were treated with the 7 lignans, and then each cell was washed twice with ginger blend and PBS, and 4% paraformaldehyde. It was fixed for 15 minutes. Cells were stained with 500 µL of Hoechst 33258 (5 µg/mL) and 500 µL propidium iodide (PI, 5 µg/mL) for 30 min at room temperature, and apoptotic cells were subjected to Leica DMLB fluorescence amplification (DMLB fluorescence). was observed using an amplifying focal point (Wetzlar, Germany). The IC50 measured by this method is shown in Table 1 below.

number compound name IC50 (μM) AGS Hela HT29 Raw264.7 One Schisandrin A - - - 4.43±0.24 2 (-)-Gomisin K1 - 5.46±0.24 - 7.03±0.22 3 Gomisin J - 6.51±0.26 - 6.54±0.14 4 Gomisin A 14.81±1.02 13.76±0.38 - 17.51±0.64 5 Angeloyl gomisin H 12.94±0.12 9.36±0.39 7.94±0.19 15.18±0.91 6 Schisandrin - - - 15.42±0.59 7 Gomisin C - - - 3.22±0.09

As a result of the MTT analysis, Schisandrin A, Schisandrin and Gomisin C of the present invention did not show cytotoxicity in cancer cell lines, so they were excluded from the compound candidates having anticancer effect.

2-2. Confirmation of apoptosis (apoptosis) activity of lignan compounds showing anticancer activity

Uterine cancer cell line (Hela) was treated with compounds 2 to 5 of the present invention, followed by Hoechst 33258 and propidium iodide (PI) staining, and imaged as shown in FIG. 3a, and compound treatment The level of apoptosis (apoptosis) was observed as compared to the control group (con) that did not. As a result of comparing and observing Hoechst 33258 staining (blue) and PI staining (red), uterine cancer cells treated with compounds 2 to 5 actively apoptosis, confirming the anticancer effect of the treated compounds on uterine cancer. .

In addition, compounds 4 and 5 of the present invention, which showed anticancer activity in uterine cancer cell lines (AGS), were treated in uterine cancer cell lines, followed by Hoechst 33258 and propidium iodide (PI) staining, It was imaged as shown in 3b, and the level of apoptosis was observed compared to the control group (con) not treated with the compound. As a result of comparative observation of Hoechst 33258 staining (blue) and PI staining (red), the uterine cancer cells treated with compounds 4 and 5 actively apoptosis, confirming the anticancer effect of the treated compounds on uterine cancer. there was.

In addition, the colorectal cancer cell line was treated with compound No. 5 of the present invention, which showed anticancer activity in the colon cancer cell line (HT29), and then stained with Hoechst 33258 and propidium iodide (PI), FIG. 3c It was imaged as shown in , and the level of apoptosis was observed compared to the control group (con) not treated with the compound. As a result of comparative observation of Hoechst 33258 staining (blue) and PI staining (red), apoptosis occurred actively in colorectal cancer cells treated with compound 5, confirming the anticancer effect of the treated compounds on colorectal cancer. .

Through the above results, the present inventors were able to confirm the anticancer effect of (-)-Gomisin K1(2), Gomisin J(3), Gomisin A(4) and Angeloyl gomisin H(5) among the lignan compounds.

The description of the present invention stated above is for illustration, and those of ordinary skill in the art to which the present invention pertains can understand that it can be easily modified into other specific forms without changing the technical spirit or essential features of the present invention. There will be. Therefore, it should be understood that the embodiments described above are illustrative in all respects and not restrictive.

Claims (8)

A pharmaceutical composition for preventing or treating cancer comprising a compound represented by the following Chemical Formula 1 or Chemical Formula 2, an isomer thereof, or a pharmaceutically acceptable salt thereof as an active ingredient:
[Formula 1]

[Formula 2]

In Formula 1 or 2,
Wherein R ₁ is a C _1-3 alkoxy group or a hydroxyl group;
wherein R ₂ is a C _1-3 alkoxy group;
wherein R ₃ is a C _1-3 alkoxy group, a hydroxy group or an angeloyl group;
wherein R ₄ is hydrogen or a hydroxyl group;
wherein R ₅ is hydrogen or a benzoyl group; and
Wherein R ₆ is a C _1-3 alkoxy group, a hydroxy group, or an angeloyl group.
The method of claim 1,
The compound is characterized in that derived from the fruit of Schisandra, the composition.
The method of claim 1,
The compound is (-)-Gomisin K1, Gomisin J, Gomisin A and Angeloyl gomisin H, characterized in that selected from the group consisting of, the composition.
The method of claim 1,
The cancer is brain tumor, head and neck cancer, breast cancer, lung cancer, esophageal cancer, stomach cancer, duodenal cancer, appendix cancer, colorectal cancer, rectal cancer, liver cancer, pancreatic cancer, gallbladder cancer, bile duct cancer, anal cancer, renal cancer, ureter cancer, bladder cancer, prostate cancer, penile cancer , Testicular cancer, uterine cancer, ovarian cancer, vulvar cancer, vaginal cancer or skin cancer, characterized in that, the composition.
A health functional food composition for the prevention or improvement of cancer, comprising a compound represented by the following Chemical Formula 1 or Chemical Formula 2, an isomer thereof, or a pharmaceutically acceptable salt thereof as an active ingredient:
[Formula 1]

[Formula 2]

In Formula 1 or 2,
Wherein R ₁ is a C _1-3 alkoxy group or a hydroxyl group;
wherein R ₂ is a C _1-3 alkoxy group;
wherein R ₃ is a C _1-3 alkoxy group, a hydroxy group or an angeloyl group;
wherein R ₄ is hydrogen or a hydroxyl group;
wherein R ₅ is hydrogen or a benzoyl group; and
Wherein R ₆ is a C _1-3 alkoxy group, a hydroxy group, or an angeloyl group.
7. The method of claim 6,
The compound is characterized in that derived from the fruit of Schisandra, the composition.
7. The method of claim 6,
The compound is (-)-Gomisin K1, Gomisin J, Gomisin A and Angeloyl gomisin H, characterized in that selected from the group consisting of, the composition.
7. The method of claim 6,
The cancer is brain tumor, head and neck cancer, breast cancer, lung cancer, esophageal cancer, stomach cancer, duodenal cancer, appendix cancer, colorectal cancer, rectal cancer, liver cancer, pancreatic cancer, gallbladder cancer, bile duct cancer, anal cancer, renal cancer, ureter cancer, bladder cancer, prostate cancer, penile cancer , Testicular cancer, uterine cancer, ovarian cancer, vulvar cancer, vaginal cancer or skin cancer, characterized in that, the composition.

Images